

SCHIZOPHRENIA RESEARCH

AN OFFICIAL JOURNAL OF THE SCHIZOPHRENIA
INTERNATIONAL RESEARCH SOCIETY

Editor-in-chief

Matcheri Keshavan, MD
Stanley Cobb Professor of Psychiatry
Harvard Medical School and Beth Israel Deaconess
Medical Center Boston, Massachusetts
E-mail: mkeshava@bidmc.harvard.edu

Founding Editors-in-chief

Henry A. Nasrallah, MD
The Sydney W. Souers Professor and Chairman
Department of Psychiatry and Behavioral Neuroscience
Saint Louis University School of Medicine
1438 S. Grand Blvd, St. Louis, MO, 63104, U.S.A.
E-mail: hnasral@slu.edu
Amelia T. Nasrallah
Senior Managing Editor (for the St. Louis Office)
E-mail: amelia.nasrallah@uc.edu

Lynn E. DeLisi, MD
Attending Psychiatrist
VA Boston Healthcare System
Professor of Psychiatry
Harvard Medical School
940 Belmont Ave, Brockton, Mass 02301, U.S.A.
E-mail: DeLisi76@AOL.com

Deputy Editors

Paola Dazzan, PhD
London, U.K.
Sophia Vinogradov, MD
Minneapolis, MN, U.S.A.

Associate Editors

Konasale Prasad
Pittsburgh, Pennsylvania, USA
Jeffrey R. Bishop, PharmD, MS, BCPP
Minneapolis, MN
Urvakhsh Mehta, MD
Karnataka, India

Assistant editor

Paulo Lizano, PhD
Boston, MA, U.S.A.

Digital Psychiatry Editor

John Torous, MD
Boston, Massachusetts, USA

Editorial board

J. Addington, Canada	A.A. Grace, U.S.A.	A. Malhotra, U.S.A.	S.G. Schwab, Australia
A. Anticevic, U.S.A.	M.F. Green, U.S.A.	S.R. Marder, U.S.A.	M.E. Shenton, U.S.A.
D.L. Braff, U.S.A.	R.E. Gur, U.S.A.	D. Mathalon, U.S.A.	V.H. Srihari, U.S.A.
P. Buckley, U.S.A.	P.J. Harrison, U.K.	R. McCullumsmith, U.S.A.	M. Takeda, Japan
K. Cadenhead, U.S.A.	P.D. Harvey, U.S.A.	P. McGorry, Australia	C.A. Tamminga, U.S.A.
A. Carlsson, Sweden	S. Heckers, U.S.A.	J.J. McGrath, Australia	R. Tandon, U.S.A.
E.Y. Chen, China	D.C. Javitt, U.S.A.	P. McGuire, U.K.	S. Tianmei, P.R. China
C. Correll, U.S.A.	R.S. Kahn, The Netherlands	K. Mueser, U.S.A.	H. Verdoux, France
J.G. Csernansky, U.S.A.	S. Kapur, U.K.	R.M. Murray, U.K.	A. Vita, Italy
M. Davidson, Israel	R. Keefe, U.S.A.	K. Nuechterlein, U.S.A.	J.L. Waddington, U.K.
M. De Hert, Belgium	S. Leucht, Germany	J.J. van Os, The Netherlands	C.S. Weickert, Australia
R. Emsley, South Africa	D.A. Lewis, U.S.A.	C. Pantelis, Australia	D.R. Weinberger, U.S.A.
R. Freedman, U.S.A.	J.A. Lieberman, U.S.A.	S. Park, U.S.A.	T. Wykes, U.K.
J. Ford, U.S.A.	D. Malaspina, U.S.A.	K.R. Prasad, U.S.A.	A. Yung, Australia
D. Goff, U.S.A.		A. Sawa, U.S.A.	R.B. Zipursky, Canada
		S.C. Schulz, U.S.A.	

Aims and scope. *Schizophrenia Research* provides rapid publication of new international research that contributes to the understanding of schizophrenia and related disorders. The journal brings together previously separated biological, clinical and psychological research on this disorder, and stimulates the synthesis of clinical and research data into cohesive hypotheses.

Types of papers. (1) Full-length papers: 4000 words. (2) Short communications: 1000–1500 words. (3) Letters to the Editors: 600–800 words, 10 references, 1 figure or table. (4) Special solicited research and/or reviews. (5) Invited comments or hypotheses. (6) Editorials. (7) Schizophrenia meeting reviews: solicited and/or submitted. (8) Book reviews.

Submission of manuscripts. Submission to *Schizophrenia Research* proceeds totally online. To access the online submission system please visit <http://ees.elsevier.com/schres>. There is an online tutorial for authors and online support for technical problems or questions via Elsevier's Author Support team (authorsupport@elsevier.com).

Manuscripts from the Americas should be submitted via the online submission system to Professor H.A. Nasrallah. Manuscripts from the rest of the world should be submitted to Professor L.E. DeLisi.

Manuscripts are only accepted on the understanding that: (1) they deal with original research and are subject to editorial revision; (2) they have not been and will not be published in whole or in part in any other journal; (3) copyright is transferred from the author to the publisher; (4) the recommendations from the Declaration of Helsinki and the internationally principles for the care and use of experimental animals have been adhered to; (5) any potential or actual conflicts of interest are declared in the submission letter accompanying the manuscript at submission stage.